BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Norona LM, Nguyen DG, Gerber DA, Presnell SC, LeCluyse EL. Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues. Toxicol Sci 2016;154:354-67. [PMID: 27605418 DOI: 10.1093/toxsci/kfw169] [Cited by in Crossref: 85] [Cited by in F6Publishing: 74] [Article Influence: 14.2] [Reference Citation Analysis]
Number Citing Articles
1 Baze A, Parmentier C, Hendriks DFG, Hurrell T, Heyd B, Bachellier P, Schuster C, Ingelman-Sundberg M, Richert L. Three-Dimensional Spheroid Primary Human Hepatocytes in Monoculture and Coculture with Nonparenchymal Cells. Tissue Eng Part C Methods 2018;24:534-45. [PMID: 30101670 DOI: 10.1089/ten.TEC.2018.0134] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
2 Ware BR, Durham MJ, Monckton CP, Khetani SR. A Cell Culture Platform to Maintain Long-term Phenotype of Primary Human Hepatocytes and Endothelial Cells. Cell Mol Gastroenterol Hepatol 2018;5:187-207. [PMID: 29379855 DOI: 10.1016/j.jcmgh.2017.11.007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
3 Zhang B, Korolj A, Lai BFL, Radisic M. Advances in organ-on-a-chip engineering. Nat Rev Mater 2018;3:257-78. [DOI: 10.1038/s41578-018-0034-7] [Cited by in Crossref: 324] [Cited by in F6Publishing: 130] [Article Influence: 81.0] [Reference Citation Analysis]
4 Underhill GH, Khetani SR. Advances in Engineered Human Liver Platforms for Drug Metabolism Studies. Drug Metab Dispos 2018;46:1626-37. [PMID: 30135245 DOI: 10.1124/dmd.118.083295] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
5 [DOI: 10.1101/505396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Sacchi M, Bansal R, Rouwkema J. Bioengineered 3D Models to Recapitulate Tissue Fibrosis. Trends Biotechnol 2020;38:623-36. [PMID: 31952833 DOI: 10.1016/j.tibtech.2019.12.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
7 Van Ness KP, Cesar F, Yeung CK, Himmelfarb J, Kelly EJ. Microphysiological systems in adsorption, distribution, metabolism, and elimination sciences. Clin Transl Sci 2021. [PMID: 34378335 DOI: 10.1111/cts.13132] [Reference Citation Analysis]
8 Hurrell T, Kastrinou-Lampou V, Fardellas A, Hendriks DFG, Nordling Å, Johansson I, Baze A, Parmentier C, Richert L, Ingelman-Sundberg M. Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis. Cells 2020;9:E964. [PMID: 32295224 DOI: 10.3390/cells9040964] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
9 Kukla DA, Khetani SR. Bioengineered Liver Models for Investigating Disease Pathogenesis and Regenerative Medicine. Semin Liver Dis 2021;41:368-92. [PMID: 34139785 DOI: 10.1055/s-0041-1731016] [Reference Citation Analysis]
10 Ramadan Q, Fardous RS, Hazaymeh R, Alshmmari S, Zourob M. Pharmacokinetics-On-a-Chip: In Vitro Microphysiological Models for Emulating of Drugs ADME. Adv Biol (Weinh) 2021;:e2100775. [PMID: 34323392 DOI: 10.1002/adbi.202100775] [Reference Citation Analysis]
11 Oakley F, Gee LM, Sheerin NS, Borthwick LA. Implementation of pre-clinical methodologies to study fibrosis and test anti-fibrotic therapy. Curr Opin Pharmacol 2019;49:95-101. [PMID: 31731225 DOI: 10.1016/j.coph.2019.10.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kostrzewski T, Snow S, Battle AL, Peel S, Ahmad Z, Basak J, Surakala M, Bornot A, Lindgren J, Ryaboshapkina M, Clausen M, Lindén D, Maass C, Young LM, Corrigan A, Ewart L, Hughes D. Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. Commun Biol 2021;4:1080. [PMID: 34526653 DOI: 10.1038/s42003-021-02616-x] [Reference Citation Analysis]
13 Kim J, Kim Y, Choi J, Jung H, Lee K, Kang J, Park N, Rim YA, Nam Y, Ju JH. Recapitulation of methotrexate hepatotoxicity with induced pluripotent stem cell-derived hepatocytes from patients with rheumatoid arthritis. Stem Cell Res Ther 2018;9:357. [PMID: 30594247 DOI: 10.1186/s13287-018-1100-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
14 Moldovan NI. Three-Dimensional Bioprinting of Anatomically Realistic Tissue Constructs for Disease Modeling and Drug Testing. Tissue Eng Part C Methods 2021;27:225-31. [PMID: 33446076 DOI: 10.1089/ten.TEC.2020.0293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Gough A, Soto-Gutierrez A, Vernetti L, Ebrahimkhani MR, Stern AM, Taylor DL. Human biomimetic liver microphysiology systems in drug development and precision medicine. Nat Rev Gastroenterol Hepatol 2021;18:252-68. [PMID: 33335282 DOI: 10.1038/s41575-020-00386-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
16 Liu Y, Gill E, Shery Huang YY. Microfluidic on-chip biomimicry for 3D cell culture: a fit-for-purpose investigation from the end user standpoint. Future Sci OA 2017;3:FSO173. [PMID: 28670465 DOI: 10.4155/fsoa-2016-0084] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
17 Heydari Z, Najimi M, Mirzaei H, Shpichka A, Ruoss M, Farzaneh Z, Montazeri L, Piryaei A, Timashev P, Gramignoli R, Nussler A, Baharvand H, Vosough M. Tissue Engineering in Liver Regenerative Medicine: Insights into Novel Translational Technologies. Cells 2020;9:E304. [PMID: 32012725 DOI: 10.3390/cells9020304] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
18 Maharjan S, Bonilla D, Sindurakar P, Li H, Li W, Duarte S, Zarrinpar A, Zhang YS. 3D human nonalcoholic hepatic steatosis and fibrosis models. Bio-des Manuf 2021;4:157-70. [DOI: 10.1007/s42242-020-00121-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
19 Deng J, Wei W, Chen Z, Lin B, Zhao W, Luo Y, Zhang X. Engineered Liver-on-a-Chip Platform to Mimic Liver Functions and Its Biomedical Applications: A Review. Micromachines (Basel) 2019;10:E676. [PMID: 31591365 DOI: 10.3390/mi10100676] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 14.7] [Reference Citation Analysis]
20 Ravanbakhsh H, Karamzadeh V, Bao G, Mongeau L, Juncker D, Zhang YS. Emerging Technologies in Multi-Material Bioprinting. Adv Mater 2021;:e2104730. [PMID: 34596923 DOI: 10.1002/adma.202104730] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Han W, Wu Q, Zhang X, Duan Z. Innovation for hepatotoxicity in vitro research models: A review: Innovation for hepatotoxicity in vitro research models. J Appl Toxicol 2019;39:146-62. [DOI: 10.1002/jat.3711] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
22 Olgasi C, Cucci A, Follenzi A. iPSC-Derived Liver Organoids: A Journey from Drug Screening, to Disease Modeling, Arriving to Regenerative Medicine. Int J Mol Sci 2020;21:E6215. [PMID: 32867371 DOI: 10.3390/ijms21176215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
23 Ware BR, Brown GE, Soldatow VY, LeCluyse EL, Khetani SR. Long-Term Engineered Cultures of Primary Mouse Hepatocytes for Strain and Species Comparison Studies During Drug Development. Gene Expr 2019;19:199-214. [PMID: 31340881 DOI: 10.3727/105221619X15638857793317] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
24 Fonseca AC, Melchels FPW, Ferreira MJS, Moxon SR, Potjewyd G, Dargaville TR, Kimber SJ, Domingos M. Emulating Human Tissues and Organs: A Bioprinting Perspective Toward Personalized Medicine. Chem Rev 2020;120:11128-74. [PMID: 32937071 DOI: 10.1021/acs.chemrev.0c00342] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
25 Lawlor KT, Vanslambrouck JM, Higgins JW, Chambon A, Bishard K, Arndt D, Er PX, Wilson SB, Howden SE, Tan KS, Li F, Hale LJ, Shepherd B, Pentoney S, Presnell SC, Chen AE, Little MH. Cellular extrusion bioprinting improves kidney organoid reproducibility and conformation. Nat Mater 2021;20:260-71. [PMID: 33230326 DOI: 10.1038/s41563-020-00853-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
26 Mannaerts I, Eysackers N, Anne van Os E, Verhulst S, Roosens T, Smout A, Hierlemann A, Frey O, Leite SB, van Grunsven LA. The fibrotic response of primary liver spheroids recapitulates in vivo hepatic stellate cell activation. Biomaterials 2020;261:120335. [PMID: 32891040 DOI: 10.1016/j.biomaterials.2020.120335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Norona LM, Nguyen DG, Gerber DA, Presnell SC, Mosedale M, Watkins PB. Bioprinted liver provides early insight into the role of Kupffer cells in TGF-β1 and methotrexate-induced fibrogenesis. PLoS One 2019;14:e0208958. [PMID: 30601836 DOI: 10.1371/journal.pone.0208958] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 10.7] [Reference Citation Analysis]
28 Ardalani H, Sengupta S, Harms V, Vickerman V, Thomson JA, Murphy WL. 3-D culture and endothelial cells improve maturity of human pluripotent stem cell-derived hepatocytes. Acta Biomater. 2019;95:371-381. [PMID: 31362140 DOI: 10.1016/j.actbio.2019.07.047] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
29 Shankaran A, Prasad K, Chaudhari S, Brand A, Satyamoorthy K. Advances in development and application of human organoids. 3 Biotech 2021;11:257. [PMID: 33977021 DOI: 10.1007/s13205-021-02815-7] [Reference Citation Analysis]
30 Weinhart M, Hocke A, Hippenstiel S, Kurreck J, Hedtrich S. 3D organ models-Revolution in pharmacological research? Pharmacol Res 2019;139:446-51. [PMID: 30395949 DOI: 10.1016/j.phrs.2018.11.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
31 Mehrotra S, Moses JC, Bandyopadhyay A, Mandal BB. 3D Printing/Bioprinting Based Tailoring of in Vitro Tissue Models: Recent Advances and Challenges. ACS Appl Bio Mater 2019;2:1385-405. [DOI: 10.1021/acsabm.9b00073] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
32 Underhill GH, Khetani SR. Emerging trends in modeling human liver disease in vitro. APL Bioeng 2019;3:040902. [PMID: 31893256 DOI: 10.1063/1.5119090] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
33 Saydmohammed M, Jha A, Mahajan V, Gavlock D, Shun TY, DeBiasio R, Lefever D, Li X, Reese C, Kershaw EE, Yechoor V, Behari J, Soto-Gutierrez A, Vernetti L, Stern A, Gough A, Miedel MT, Lansing Taylor D. Quantifying the progression of non-alcoholic fatty liver disease in human biomimetic liver microphysiology systems with fluorescent protein biosensors. Exp Biol Med (Maywood) 2021;:15353702211009228. [PMID: 33957803 DOI: 10.1177/15353702211009228] [Reference Citation Analysis]
34 Haugabook SJ, Ferrer M, Ottinger EA. In vitro and in vivo translational models for rare liver diseases. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2019;1865:1003-18. [DOI: 10.1016/j.bbadis.2018.07.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
35 Inoue T, Iwazaki N, Araki T, Hitotsumachi H. Human-Induced Pluripotent Stem Cell-Derived Hepatocytes and their Culturing Methods to Maintain Liver Functions for Pharmacokinetics and Safety Evaluation of Pharmaceuticals. Curr Pharm Biotechnol 2020;21:773-9. [PMID: 32003687 DOI: 10.2174/1389201021666200131123524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Davidson MD, Kukla DA, Khetani SR. Microengineered cultures containing human hepatic stellate cells and hepatocytes for drug development. Integr Biol (Camb) 2017;9:662-77. [PMID: 28702667 DOI: 10.1039/c7ib00027h] [Cited by in Crossref: 33] [Cited by in F6Publishing: 15] [Article Influence: 8.3] [Reference Citation Analysis]
37 Underhill GH, Khetani SR. Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies. Cell Mol Gastroenterol Hepatol 2018;5:426-439.e1. [PMID: 29675458 DOI: 10.1016/j.jcmgh.2017.11.012] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 14.8] [Reference Citation Analysis]
38 Bouwmeester MC, Bernal PN, Oosterhoff LA, van Wolferen ME, Lehmann V, Vermaas M, Buchholz MB, Peiffer QC, Malda J, van der Laan LJW, Kramer NI, Schneeberger K, Levato R, Spee B. Bioprinting of Human Liver-Derived Epithelial Organoids for Toxicity Studies. Macromol Biosci 2021;:e2100327. [PMID: 34559943 DOI: 10.1002/mabi.202100327] [Reference Citation Analysis]
39 Brown GE, Khetani SR. Microfabrication of liver and heart tissues for drug development. Philos Trans R Soc Lond B Biol Sci 2018;373:20170225. [PMID: 29786560 DOI: 10.1098/rstb.2017.0225] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
40 Xia Z, Jin S, Ye K. Tissue and Organ 3D Bioprinting. SLAS Technol 2018;23:301-14. [PMID: 29474789 DOI: 10.1177/2472630318760515] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
41 Pfuhler S, van Benthem J, Curren R, Doak SH, Dusinska M, Hayashi M, Heflich RH, Kidd D, Kirkland D, Luan Y, Ouedraogo G, Reisinger K, Sofuni T, van Acker F, Yang Y, Corvi R. Use of in vitro 3D tissue models in genotoxicity testing: Strategic fit, validation status and way forward. Report of the working group from the 7th International Workshop on Genotoxicity Testing (IWGT). Mutat Res 2020;850-851:503135. [PMID: 32247552 DOI: 10.1016/j.mrgentox.2020.503135] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
42 Miller GW. 2018 Toxicological Sciences Paper of the Year: Assessing Fibrogenesis Using 3D-Printed Liver Tissues. Toxicol Sci 2018;162:339-40. [PMID: 29590488 DOI: 10.1093/toxsci/kfy033] [Reference Citation Analysis]
43 Hwang DG, Choi YM, Jang J. 3D Bioprinting-Based Vascularized Tissue Models Mimicking Tissue-Specific Architecture and Pathophysiology for in vitro Studies. Front Bioeng Biotechnol 2021;9:685507. [PMID: 34136473 DOI: 10.3389/fbioe.2021.685507] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
44 Gajula SNR, Nadimpalli N, Sonti R. Drug metabolic stability in early drug discovery to develop potential lead compounds. Drug Metab Rev 2021;53:459-77. [PMID: 34406889 DOI: 10.1080/03602532.2021.1970178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Rao S, Hossain T, Mahmoudi T. 3D human liver organoids: An in vitro platform to investigate HBV infection, replication and liver tumorigenesis. Cancer Lett 2021;506:35-44. [PMID: 33675983 DOI: 10.1016/j.canlet.2021.02.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Pridgeon CS, Schlott C, Wong MW, Heringa MB, Heckel T, Leedale J, Launay L, Gryshkova V, Przyborski S, Bearon RN, Wilkinson EL, Ansari T, Greenman J, Hendriks DFG, Gibbs S, Sidaway J, Sison-Young RL, Walker P, Cross MJ, Park BK, Goldring CEP. Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms. Arch Toxicol 2018;92:557-69. [PMID: 29362863 DOI: 10.1007/s00204-018-2152-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
47 Hardwick RN, Viergever C, Chen AE, Nguyen DG. 3D bioengineered tissues: From advancements in in vitro safety to new horizons in disease modeling. Clin Pharmacol Ther 2017;101:453-7. [PMID: 27864923 DOI: 10.1002/cpt.569] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
48 Kukla DA, Crampton AL, Wood DK, Khetani SR. Microscale Collagen and Fibroblast Interactions Enhance Primary Human Hepatocyte Functions in Three-Dimensional Models. Gene Expr 2020;20:1-18. [PMID: 32290899 DOI: 10.3727/105221620X15868728381608] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
49 Ma L, Wu Y, Li Y, Aazmi A, Zhou H, Zhang B, Yang H. Current Advances on 3D-Bioprinted Liver Tissue Models. Adv Healthc Mater 2020;9:e2001517. [PMID: 33073522 DOI: 10.1002/adhm.202001517] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
50 Otieno MA, Gan J, Proctor W. Status and Future of 3D Cell Culture in Toxicity Testing. In: Chen M, Will Y, editors. Drug-Induced Liver Toxicity. New York: Springer; 2018. pp. 249-61. [DOI: 10.1007/978-1-4939-7677-5_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Rezania V, Coombe D, Tuszynski J. Liver Bioreactor Design Issues of Fluid Flow and Zonation, Fibrosis, and Mechanics: A Computational Perspective. J Funct Biomater 2020;11:E13. [PMID: 32121053 DOI: 10.3390/jfb11010013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Nguyen DG, Pentoney SL. Bioprinted three dimensional human tissues for toxicology and disease modeling. Drug Discovery Today: Technologies 2017;23:37-44. [DOI: 10.1016/j.ddtec.2017.03.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
53 Gori M, Giannitelli SM, Torre M, Mozetic P, Abbruzzese F, Trombetta M, Traversa E, Moroni L, Rainer A. Biofabrication of Hepatic Constructs by 3D Bioprinting of a Cell‐Laden Thermogel: An Effective Tool to Assess Drug‐Induced Hepatotoxic Response. Adv Healthcare Mater 2020;9:2001163. [DOI: 10.1002/adhm.202001163] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
54 Nautiyal M, Qasem RJ, Fallon JK, Wolf KK, Liu J, Dixon D, Smith PC, Mosedale M. Characterization of primary mouse hepatocyte spheroids as a model system to support investigations of drug-induced liver injury. Toxicol In Vitro 2021;70:105010. [PMID: 33022361 DOI: 10.1016/j.tiv.2020.105010] [Reference Citation Analysis]
55 Lam DTUH, Dan YY, Chan YS, Ng HH. Emerging liver organoid platforms and technologies. Cell Regen 2021;10:27. [PMID: 34341842 DOI: 10.1186/s13619-021-00089-1] [Reference Citation Analysis]
56 Davidson MD, Khetani SR. Intermittent Starvation Extends the Functional Lifetime of Primary Human Hepatocyte Cultures. Toxicol Sci 2020;174:266-77. [PMID: 31977024 DOI: 10.1093/toxsci/kfaa003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
57 Kryou C, Leva V, Chatzipetrou M, Zergioti I. Bioprinting for Liver Transplantation. Bioengineering (Basel) 2019;6:E95. [PMID: 31658719 DOI: 10.3390/bioengineering6040095] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
58 van Grunsven LA. 3D in vitro models of liver fibrosis. Advanced Drug Delivery Reviews 2017;121:133-46. [DOI: 10.1016/j.addr.2017.07.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 11.0] [Reference Citation Analysis]
59 Mandrycky CJ, Howard CC, Rayner SG, Shin YJ, Zheng Y. Organ-on-a-chip systems for vascular biology. J Mol Cell Cardiol 2021;159:1-13. [PMID: 34118217 DOI: 10.1016/j.yjmcc.2021.06.002] [Reference Citation Analysis]
60 Willson K, Ke D, Kengla C, Atala A, Murphy SV. Extrusion-Based Bioprinting: Current Standards and Relevancy for Human-Sized Tissue Fabrication. Methods Mol Biol 2020;2140:65-92. [PMID: 32207106 DOI: 10.1007/978-1-0716-0520-2_5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
61 Wang JZ, Xiong NY, Zhao LZ, Hu JT, Kong DC, Yuan JY. Review fantastic medical implications of 3D-printing in liver surgeries, liver regeneration, liver transplantation and drug hepatotoxicity testing: A review. Int J Surg 2018;56:1-6. [PMID: 29886280 DOI: 10.1016/j.ijsu.2018.06.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
62 Mosedale M, Watkins PB. Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury. J Med Chem 2020;63:6436-61. [PMID: 32037821 DOI: 10.1021/acs.jmedchem.9b01297] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
63 Fetah K, Tebon P, Goudie MJ, Eichenbaum J, Ren L, Barros N, Nasiri R, Ahadian S, Ashammakhi N, Dokmeci MR, Khademhosseini A. The emergence of 3D bioprinting in organ-on-chip systems. Prog Biomed Eng 2019;1:012001. [DOI: 10.1088/2516-1091/ab23df] [Cited by in Crossref: 36] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
64 Guzzi EA, Tibbitt MW. Additive Manufacturing of Precision Biomaterials. Adv Mater 2020;32:e1901994. [PMID: 31423679 DOI: 10.1002/adma.201901994] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 13.7] [Reference Citation Analysis]
65 Donoghue L, Nguyen KT, Graham C, Sethu P. Tissue Chips and Microphysiological Systems for Disease Modeling and Drug Testing. Micromachines (Basel) 2021;12:139. [PMID: 33525451 DOI: 10.3390/mi12020139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Retting K, Carter D, Crogan-grundy C, Khatiwala C, Norona L, Paffenroth E, Hanumegowda U, Chen A, Hazelwood L, Lehman-mckeeman L, Presnell S. Modeling Liver Biology and the Tissue Response to Injury in Bioprinted Human Liver Tissues. Applied In Vitro Toxicology 2018;4:288-303. [DOI: 10.1089/aivt.2018.0015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
67 Zhang B, Radisic M. Organ-on-a-chip devices advance to market. Lab Chip 2017;17:2395-420. [PMID: 28617487 DOI: 10.1039/c6lc01554a] [Cited by in Crossref: 183] [Cited by in F6Publishing: 74] [Article Influence: 45.8] [Reference Citation Analysis]
68 Jiang J, Pieterman CD, Ertaylan G, Peeters RLM, de Kok TMCM. The application of omics-based human liver platforms for investigating the mechanism of drug-induced hepatotoxicity in vitro. Arch Toxicol 2019;93:3067-98. [PMID: 31586243 DOI: 10.1007/s00204-019-02585-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
69 Tetsuka K, Ohbuchi M, Tabata K. Recent Progress in Hepatocyte Culture Models and Their Application to the Assessment of Drug Metabolism, Transport, and Toxicity in Drug Discovery: The Value of Tissue Engineering for the Successful Development of a Microphysiological System. J Pharm Sci 2017;106:2302-11. [PMID: 28533121 DOI: 10.1016/j.xphs.2017.05.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
70 Harrison SP, Baumgarten SF, Verma R, Lunov O, Dejneka A, Sullivan GJ. Liver Organoids: Recent Developments, Limitations and Potential. Front Med (Lausanne) 2021;8:574047. [PMID: 34026769 DOI: 10.3389/fmed.2021.574047] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
71 Monckton CP, Brown GE, Khetani SR. Latest impact of engineered human liver platforms on drug development. APL Bioeng 2021;5:031506. [PMID: 34286173 DOI: 10.1063/5.0051765] [Reference Citation Analysis]
72 Gill EL, Li X, Birch MA, Huang YYS. Multi-length scale bioprinting towards simulating microenvironmental cues. Biodes Manuf 2018;1:77-88. [PMID: 30546920 DOI: 10.1007/s42242-018-0014-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
73 Ehrlich A, Duche D, Ouedraogo G, Nahmias Y. Challenges and Opportunities in the Design of Liver-on-Chip Microdevices. Annu Rev Biomed Eng 2019;21:219-39. [PMID: 31167098 DOI: 10.1146/annurev-bioeng-060418-052305] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 14.0] [Reference Citation Analysis]
74 Orbach SM, Ford AJ, Saverot SE, Rajagopalan P. Multi-cellular transitional organotypic models to investigate liver fibrosis. Acta Biomater 2018;82:79-92. [PMID: 30316024 DOI: 10.1016/j.actbio.2018.10.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
75 Sistare FD, Mattes WB, Lecluyse EL. The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development. ILAR J 2017;57:186-211. [DOI: 10.1093/ilar/ilw025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
76 Segovia-zafra A, Di Zeo-sánchez DE, López-gómez C, Pérez-valdés Z, García-fuentes E, Andrade RJ, Lucena MI, Villanueva-paz M. Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction. Acta Pharmaceutica Sinica B 2021;11:3685-726. [DOI: 10.1016/j.apsb.2021.11.013] [Reference Citation Analysis]
77 Fernández-Colino A, Iop L, Ventura Ferreira MS, Mela P. Fibrosis in tissue engineering and regenerative medicine: treat or trigger? Adv Drug Deliv Rev 2019;146:17-36. [PMID: 31295523 DOI: 10.1016/j.addr.2019.07.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]